Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET–CT-based study
Y Pan, J Chen, H Lin, L-B Tang, H-H Yan, J-X Zeng, S Dong, L-X Yan, Y Yang, D-J Li, Y-L Wu · 2026
Read Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET–CT-based study by Y Pan, J Chen, H Lin, L-B Tang, H-H Yan, J-X Zeng, S Dong, L-X Yan, Y Yang, D-J Li, Y-L Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13573743.txt.
Description
Pan and co-authors study a scan trap in lung cancer care in a 2026 article. Patients with removable lung tumors now often get immune therapy before surgery. Sometimes the tumor looks bigger on scans after treatment, yet the growth is a false alarm, swelling from immune attack rather than cancer spread. Mistaking it for true growth can cancel surgery a patient still needs.
The team reviewed 283 patients treated before surgery, most with immune drugs and some with targeted drugs, and compared two standard ways of reading their scans. By the stricter reading, far more patients were flagged as progressing, and every progression call under the looser reading fell in the immune group. The authors build a strategy, checked on a separate patient group, to tell false growth from real. Their aim is to keep operable patients on the path to surgery.
Catalog record
| CREATOR | Y Pan, J Chen, H Lin, L-B Tang, H-H Yan, J-X Zeng, S Dong, L-X Yan, Y Yang, D-J Li, Y-L Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |